Do you want to read an article? Please log in or register.
Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications
Pulmonary FibrosisBronchi
RECOMMENDED
Related content
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
RECOMMENDED
Bronchi
Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis
Respir Med.
Alcaraz-Serrano V, Fernández-Barat L, Scioscia G, Llorens-Llacuna J, Gimeno-Santos E, Herrero-Cortina B, Vàzquez N, Puig de la Bellacasa J, Gabarrús A, Amaro-Rodriguez R, Menéndez R, Torres A
doi: 10.1016/j.rmed.
RECOMMENDED
Further Publications
Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Choate R, Aksamit TR, Mannino D, Addrizzo-Harris D, Barker A, Basavaraj A, Daley CL, Daniels MLA, Eden E, DiMango A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, McShane PJ, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Winthrop KL, Stone G
doi: 10.1016/j.rmed.2020.106285
Pulmonary Fibrosis
Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients
Antimicrob Agents Chemother.
Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB
doi: 10.1128/AAC.01150-18.
RECOMMENDED
Pulmonary Fibrosis
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Am J Respir Crit Care Med.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW; OPTIMIZE Study Group
doi: 10.1164/rccm.
RECOMMENDED
Pulmonary Fibrosis
Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis
Thorax.
Harun SN, Holford NHG, Grimwood K, Wainwright CE, Hennig S, Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group.
doi: 10.1136/
RECOMMENDED
Pulmonary Fibrosis
Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir Rev
Keown K, Reid A, Moore JE, Taggart CC, Downey DG
doi: 10.1183/16000617.0011-2020
Pulmonary Fibrosis
Non-fasting bioelectrical impedance analysis in cystic fibrosis: Implications for clinical practice and research
J Cyst Fibros.
Hollander-Kraaijeveld FM, Lindeman Y, de Roos NM, Burghard M, van de Graaf EA, Heijerman HGM
doi: 10.1016/j.jcf.
RECOMMENDED
Bronchi
Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Martínez-García MÁ, Oscullo G, Barreiro E, Cuenca S, Cervera A, Padilla-Galo A, de la Rosa D, Navarro A, Giron R, Carbonero F, Castro Otero M, Casas F
doi: 10.3390/jcm9072317.